Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genasense plus Docetaxel in Relapsed/Refractory NSCLC
NCT00030641Phase 3Unknown
- Sponsor
- Genta Incorporated
- Start
- Oct 2001
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 3
01
Overview
A Phase 3 trial of oblimersen in non-small cell lung cancer (NSCLC), sponsored by Genta Incorporated. Status: unknown.
02
Drugs
oblimersen
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00030641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00030641.